Overview

Carboxyamidotriazole + RT in Treating Patients Newly Diagnosed Supratentorial GBM

Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
0
Participant gender:
All
Summary
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining radiation therapy with chemotherapy may kill more tumor cells. Phase II trial to study the effectiveness of carboxyamidotriazole plus radiation therapy in treating patients who have newly diagnosed supratentorial glioblastoma multiforme.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
National Cancer Institute (NCI)
Treatments:
Carboxyamido-triazole
Criteria
Inclusion Criteria:

- Patients must have histologically confirmed supratentorial grade IV astrocytoma
(glioblastoma multiforme)

- Patients must have measurable or non-measurable tumor on the post operative,
pretreatment MRI/CT scan (within two weeks of starting treatment)

- Patients must not have received prior radiation therapy, chemotherapy, hormonal
therapy, immunotherapy or therapy with biologic agents (including immunotoxins,
immunoconjugates, antisense, peptide receptor antagonists, interferons, interleukins,
TIL, LAK or gene therapy), or hormonal therapy for their brain tumor; glucocorticoid
therapy is allowed

- Patients must have recovered from the immediate post-operative period and be
maintained on a stable steroid regimen (no increase for the last five days)

- Absolute neutrophil count >= 1500/mm^3

- Platelets >= 100,000/mm^3

- Hemoglobin concentration >= 9.0 g/dl

- Creatinine =< 1.7mg/dL

- Total bilirubin =< 1.2 mg/dl

- Transaminases =< 2 times above the upper limits of the institutional normal

- Estimated life expectancy greater than 2 months

- Patients must give informed consent and understand the investigational nature of this
study and its potential risks and benefits

- Patients, if female and of childbearing potential must have a negative serum beta-hCG
test and must not be breast feeding; all patients with the potential for pregnancy
should be counseled and requested to follow acceptable birth control methods to avoid
conception

- Patients must have a Karnofsky performance status of >= 60%

- No other serious concurrent infection or other medical illness should be present which
would jeopardize the ability of the patient to receive the drug outlined in this
protocol with reasonable safety

- Patients must have no concurrent malignancy except curatively treated basal or
squamous cell carcinoma of the skin or carcinoma in situ; patients with prior
malignancies must be disease-free for >= five years

Exclusion Criteria:

- Patients must be able to comply with prescribed medical care

- Prior therapy for the brain tumor (except surgery)

- Prior treatment with antineoplastic agents, including CAI